Sublingual SDF-Measurement with communication and interpreting checklist to the treating physician
OtherSublingual SDF-Measurement at admission and after 24h, with communication and interpreting checklist to the treating physician
NCT Number: NCT04173221
Maintaining organ perfusion is the key to successful intensive care medicine. Shock is the most dangerous microcirculatory disorder and one of the most hazardous and lethal conditions of critically ill patients still showing high mortality rates. However, there are still ongoing controversies, how to assess microcirculation, how to predict outcome in time and how to guide specific therapy. Macrocirculation does not reflect microcirculation. Microcirculation reflects organ perfusion and correlates with the outcome. There is growing evidence that microcirculatory parameters are powerful tools to predict the outcome after cardiac arrest. Several guidelines use it as a target to guide therapy, but these recommendations base only on supporting evidence of low quality. Lactate is a late reflector of reduced organ perfusion and is of limited value for time-critical decision-making and their value as a therapeutic target. Sublingual sidestream dark-field (SDF) - measurement is a non-invasive method that reliably reflects organ perfusion. The last generation of microcirculation assessment tools are easy to use hand-held devices that use an automatic algorithm. In consequence, microcirculation has become a directly detectable physiological compartment. However, systematic investigations about this technology in shock are still lacking. DAMIS determines the value of directly assessed microcirculation on outcome in different types of shock. Therefore, this multicenter study will recruit up to 200 patients in shock. After the first measurement, patients will be randomized either to intervention or to control. The intervention consists in knowing microcirculatory parameters. A checklist will assist the treating physicians of the interventional group in explaining microcirculatory values and offering possible treatment options. Patients in the control group will be measured as well, but results will not be communicated to the treating physician.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Division of Cardiology, Pulmonary Disease and Vascular Medicine, Düsseldorf, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sublingual SDF-Measurement at admission and after 24h, with communication and interpreting checklist to the treating physician
Sublingual SDF-Measurement at admission and after 24h, without communication and interpreting checklist to the treating physician
Time frame: 30 day
relationship of bedside measurement of microcirculation with the clinical outcome in terms of mortality
Time frame: 6 and 12 months
relationship of bedside measurement of microcirculation with the clinical outcome in terms of mortality
Time frame: 90 days
relationship of bedside measurement of microcirculation with the clinical outcome in terms of length of stay
Heinrich-Heine University, Duesseldorf
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06193980
Behavior, Critical Illness
Winnipeg, Manitoba, Canada
View Trial DetailsNCT06872216
Microcirculation
Tokat Province, Turkey (Türkiye)
View Trial DetailsNCT06191913
Microcirculation
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT03044483
Infections, Inflammation
Leicester, Leicestershire, United Kingdom
View Trial Details